BD

BD CEO Tom Polen Addresses FDA 510(k) Clearance of BD Alaris™ Infusion System

Retrieved on: 
Monday, July 24, 2023

FRANKLIN LAKES, N.J., July 24, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX) Chairman, CEO and President Tom Polen issued the following message regarding the U.S. Food and Drug Administration (FDA) 510(k) clearance for the updated BD Alaris™ Infusion System :

Key Points: 
  • FRANKLIN LAKES, N.J., July 24, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX) Chairman, CEO and President Tom Polen issued the following message regarding the U.S. Food and Drug Administration (FDA) 510(k) clearance for the updated BD Alaris™ Infusion System :
    "Hello, I'm Tom Polen, chairman, CEO and president of BD.
  • I'm very pleased to announce that we have reached the important milestone of obtaining FDA 510(k) clearance of the updated BD Alaris™ Infusion System.
  • Everyone at BD is grateful for the support and patience that our customers afforded us through the 510(k) submission and review process.
  • The updated Alaris System addresses all open recalls, with the latest hardware, a new version of software, and important cybersecurity updates.

BD Receives FDA 510(k) Clearance for Updated BD Alaris™ Infusion System

Retrieved on: 
Friday, July 21, 2023

"The 510(k) clearance of the updated BD Alaris™ Infusion System has been the number one priority for our teams who have been steadfast in their efforts to achieve this milestone, consistent with our commitment to quality," said Tom Polen, chairman, CEO and president of BD.

Key Points: 
  • "The 510(k) clearance of the updated BD Alaris™ Infusion System has been the number one priority for our teams who have been steadfast in their efforts to achieve this milestone, consistent with our commitment to quality," said Tom Polen, chairman, CEO and president of BD.
  • "We are deeply committed to ensuring clinicians can continue to rely on our market leading system to meet today's most critical infusion needs.
  • "Today, a majority of hospitals in the United States use the BD Alaris™ Infusion System to safely deliver IV therapies to patients, and this comprehensive clearance provides a foundation to support a steady, reliable cadence of innovation in infusion technologies from BD.
  • For more information on the BD Alaris™ Infusion System, visit: https://www.bd.com/en-us/products-and-solutions/products/product-brands/... .

Leading Manufacturers in Switzerland Diabetes Market 2023: Medtronic's Guardian 4 Sensor Receives European Approvals - ResearchAndMarkets.com

Retrieved on: 
Friday, July 21, 2023

The Switzerland Diabetes Market is expected to reach US$ 1.99 Billion by 2028, with a compound annual growth rate (CAGR) of 4.71% during the forecast period of 2023-2028.

Key Points: 
  • The Switzerland Diabetes Market is expected to reach US$ 1.99 Billion by 2028, with a compound annual growth rate (CAGR) of 4.71% during the forecast period of 2023-2028.
  • The report highlights the escalating diabetes prevalence in Switzerland, with approximately half a million people affected by the disease.
  • The Switzerland Diabetes Market is categorized into four segments: Continuous Glucose Monitoring (CGM), Self-Monitoring Blood Glucose (SMBG), Insulin Pump, and Insulin Pen.
  • The comprehensive report, "Switzerland Diabetes Market & Forecast," provides valuable insights into the market dynamics, growth drivers, and challenges faced in diabetic care.

BD Issues FY 2022 ESG Report, Highlights Notable Progress in Energy and Waste Reduction, Health Care Access and Diversity

Retrieved on: 
Thursday, July 20, 2023

FRANKLIN LAKES, N.J., July 20, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued its Fiscal Year 2022 Environmental, Social and Governance (ESG) Report that details ongoing efforts that impact company health, human health, community health and planet health.

Key Points: 
  • BD and the BD Foundation donated more than $22.5 million in cash and products worldwide to eligible non-profit organizations to support resilient communities and expand health care access and equity.
  • As part of the company's cybersecurity governance, BD achieved ISO/IEC 27001:2022 certification in FY 2022, which demonstrates a steadfastness to maintaining world-class cybersecurity standards.
  • For more information about BD's 2030+ ESG goals and to view the company's full FY 2022 ESG Report, visit BD.com .
  • Learn more about awards and recognition for BD's ESG impact on the BD Newsroom .

Sathgen Therapeutics announces dosing of the first patient cohort with MSP008-22, a novel anti-cancer drug

Retrieved on: 
Thursday, July 20, 2023

MUMBAI, India, July 20, 2023 /PRNewswire/ -- Sathgen Therapeutics, a division of a leading chemicals conglomerate in India – Godavari Biorefineries Limited (GBL), has announced the completion of the first cohort in a Phase 1 clinical trial for their first-in-class New Chemical Entity, MSP008-22. The clinical trial program is managed by Clinexel Life Sciences, a renowned contract research organization in the health sector.

Key Points: 
  • Sathgen Therapeutics aims to develop MSP008-22 for difficult-to-treat cancers, starting with triple negative breast cancer (TNBC) and prostate cancer as proof-of-principle.
  • MSP008-22 effectively targets treatment-resistant cancer cells in preclinical models, and demonstrates an excellent safety profile with no serious adverse events in the first patient cohort.
  • Professor Sendurai Mani, Associate Director, Legorreta Cancer Center, Brown University, and Scientific Co-Founder, Sathgen Therapeutics, stated, "TNBC is responsible for 30% of breast cancer-related deaths.
  • With over 15 anti-cancer candidates in the pipeline, Sathgen Therapeutics remains committed to advancing cancer therapeutics.

Sathgen Therapeutics announces dosing of the first patient cohort with MSP008-22, a novel anti-cancer drug

Retrieved on: 
Thursday, July 20, 2023

MUMBAI, India, July 20, 2023 /PRNewswire/ -- Sathgen Therapeutics, a division of a leading chemicals conglomerate in India – Godavari Biorefineries Limited (GBL), has announced the completion of the first cohort in a Phase 1 clinical trial for their first-in-class New Chemical Entity, MSP008-22. The clinical trial program is managed by Clinexel Life Sciences, a renowned contract research organization in the health sector.

Key Points: 
  • Sathgen Therapeutics aims to develop MSP008-22 for difficult-to-treat cancers, starting with triple negative breast cancer (TNBC) and prostate cancer as proof-of-principle.
  • MSP008-22 effectively targets treatment-resistant cancer cells in preclinical models, and demonstrates an excellent safety profile with no serious adverse events in the first patient cohort.
  • Professor Sendurai Mani, Associate Director, Legorreta Cancer Center, Brown University, and Scientific Co-Founder, Sathgen Therapeutics, stated, "TNBC is responsible for 30% of breast cancer-related deaths.
  • With over 15 anti-cancer candidates in the pipeline, Sathgen Therapeutics remains committed to advancing cancer therapeutics.

EQS-News: Affluent Medical strengthens management team to advance its development

Retrieved on: 
Monday, July 17, 2023

Sébastien Ladet, CEO of Affluent Medical, commented: "I am delighted to welcome Christophe de Vregille and Benjamin Renault to the Affluent Medical management team at a time when we are approaching several decisive stages in the deployment of our development strategy.

Key Points: 
  • Sébastien Ladet, CEO of Affluent Medical, commented: "I am delighted to welcome Christophe de Vregille and Benjamin Renault to the Affluent Medical management team at a time when we are approaching several decisive stages in the deployment of our development strategy.
  • Benjamin brings a wealth of experience and knowledge in medical device development, which will be instrumental in preparing for commercialization and our expansion on international markets."
  • Benjamin Renault has over 15 years' experience in the development and international deployment of medical devices.
  • Overview of Affluent Medical’s management and leadership team:
    Christophe Giot, M.D., Chief Medical Officer and Vice President Clinical Affairs (Edwards, Terumo, Sanofi)
    Céline Buard, Marketing Director (Johnson & Johnson, BD, Eyetech Care)
    Eric Jague, Director of Regulatory Affairs (Medtronic, Fresenius Kabi)

Affluent Medical strengthens management team to advance its development.

Retrieved on: 
Monday, July 17, 2023

Affluent Medical strengthens management team to advance its development.

Key Points: 
  • Affluent Medical strengthens management team to advance its development.
  • Sébastien Ladet, CEO of Affluent Medical comments: "I am delighted to welcome Christophe de Vregille and Benjamin Renault to the Affluent Medical management team at a time when we are approaching several decisive stages in the deployment of our development strategy.
  • Benjamin Renault has over 15 years' experience in the development and international deployment of medical devices.
  • Overview of Affluent Medical’s management and leadership team:
    Christophe Giot, M.D., Chief Medical Officer and Vice President Clinical Affairs (Edwards, Terumo, Sanofi)
    Céline Buard, Marketing Director (Johnson & Johnson, BD, Eyetech Care)
    Eric Jague, Director of Regulatory Affairs (Medtronic, Fresenius Kabi)

Amid Primary Care Crisis, Workflow Services Calls for Broadening Scope of Pharmacies as Primary Providers in Paper by Former NIH Official

Retrieved on: 
Friday, July 14, 2023

MADISON, Wis., July 14, 2023 /PRNewswire/ -- Workflow Services, a comprehensive and automated platform that solves point-of-care clinical service delivery for pharmacies, recently published a paper that advocates for the permanent, expanded primary healthcare role for pharmacists.

Key Points: 
  • Providing healthcare services at pharmacies makes sense -- 90% of Americans live within five miles of a pharmacy.
  • Authored by Nancy Gagliano, MD, a former NIH official and current advisor to Workflow Services, the paper maps the complicated state-by-state regulations for pharmacies to deliver clinical services, which grew in scope during the pandemic for services such as test-to-treat therapies.
  • "When the pandemic overwhelmed the U.S. healthcare system, non-traditional settings like pharmacies stepped into a clinical role," writes Dr. Gagliano.
  • Workflow Services' footprint continues to grow with some of the most well-known pharmacies and diagnostics companies, including BD and Quidel.

NeuroSense to Participate in Upcoming ALS Conferences: European Network to Cure ALS & EverythingALS Digital Biomarkers Summit

Retrieved on: 
Tuesday, July 11, 2023

NeuroSense aims to create new partnerships at ENCALS, while strengthening our existing connections with the European ALS scientific community.

Key Points: 
  • NeuroSense aims to create new partnerships at ENCALS, while strengthening our existing connections with the European ALS scientific community.
  • NeuroSense's CEO, Alon Ben-Noon, VP of BD, Nedira Salzman-Frenkel, and Dr. Zimri, will participate in the EverythingALS Digital Biomarkers Summit: A Meeting of the Minds in ALS.
  • "NeuroSense is committed to working in collaboration with the leading minds and organizations on the forefront of advancing toward effective treatments for ALS and to improve the lives of those living with ALS and their families.
  • We look forward to participating in these important upcoming conferences," stated Alon Ben-Noon, CEO of NeuroSense.